Return to Listing

24 result(s) for Prostate

PI Name Protocol # Title
Julie Graff IRB00009892 A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
Arthur Hung IRB00011268 Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide (MDV3100) in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy
Zahi Mitri STUDY00015588 Serial Measurements of Molecular and Architectural Responses to Therapy
Kerri Winters STUDY00015921 INTense Exercise foR surviVAL among men with Metastatic Prostate Cancer (INTERVAL-GAP4): A Multicenter, Randomized, Controlled, Phase III Study
Gordon Mills STUDY00016113 Molecular Mechanisms of Tumor Evolution and Resistance to Therapy
Julie Graff STUDY00016728 Advanced ChemoHormonal Therapy for Treatment Naïve Metastatic Prostate Cancer: Apalutamide and Abiraterone Acetate with Prednisone and Androgen Deprivation Therapy after Treatment with Docetaxel and Androgen Deprivation Therapy
Rajan Kulkarni STUDY00017648 VAPORHCS/OHSU J: Isolation and analysis of circulating tumor cells (CTCs) and nucleic acids from patient blood specimens
Tom Beer STUDY00017717 VAPORHCS/OHSU J: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Julie Graff STUDY00017864 TRITON3: A Multicenter, Randomized, Open-Label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer Associated with Homologous Recombination Deficiency (protocol CO-338-063)
Kerri Winters STUDY00018000 Exercising Together: A randomized controlled trial of partnered exercise training on the health of couples coping with cancer
Tom Beer STUDY00018231 Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Kerri Winters STUDY00018354 Group Exercise Training for Fall Prevention and Functional Improvements During and After Treatment for Prostate Cancer
Jacqueline Vuky STUDY00018878 A phase 1 study of FOR46 administered every 21 days in patients with metastatic castration-resistant prostate cancer (mCRPC)
Julie Graff STUDY00019558 A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Julie Graff STUDY00019692 A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)
Julie Graff STUDY00019782 [WIRB - IAA] A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
Arthur Hung STUDY00019787 A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer (COMPPARE)
Christopher Ryan STUDY00019992 [NCI CIRB] MATCH - EAY131 - Molecular Analysis for Therapy Choice (MATCH)
Christopher Ryan STUDY00020229 [NCI CIRB] A031702 - A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Tom Beer STUDY00020325 [IntegReview IRB - IAA] A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy
Tom Beer STUDY00020481 VAPORHCS/OHSU J: A randomized, open-label, multicenter, Phase 2b study to evaluate physical function, including balance and daily activity, in participants with castration-resistant prostate cancer treated with darolutamide or enzalutamide (Bayer 20609)
Reid Thompson STUDY00020634 Development of a Machine Learning Model for Prostate Cancer Treatment Planning
Jacqueline Vuky STUDY00020692 A Phase 1/2, open-label, dose escalation and cohort expansion clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-110 in patients with metastatic castration-resistant prostate cancer
Christopher Ryan STUDY00021677 [NCI CIRB] NCICOVID - NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080